Gazyvaro

February 13, 2018February 13, 2018

UK Agency Recommends Gazyvaro for First-Line Treatment of Follicular Lymphoma

News

The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended Roche‘s Gazyvaro (obinutuzumab) as a first-line treatment for follicular lymphoma patients, after initially rejecting it. Routine use of ... Read more

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance therapy. ... Read more

July 19, 2016July 19, 2016

Gazyva Plus CHOP Brings No New Benefits to Diffuse Large B-Cell Lymphoma Patients in Phase 3 Study

News

Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) given Gazyva/Gazyvaro (obinutuzumab) plus standard chemotherapy (CHOP) do not have higher progression-free survival rates than those treated with Rituxan/MabThera (rituximab), according to new data ... Read more

June 17, 2016June 17, 2016

EU Approves Gazyvaro (obinutuzumab) as a Treatment for Advanced Follicular Lymphoma

News

Roche announced that the European Commission has approved Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy, to treat follicular lymphoma patients who have failed to respond to, or whose disease progressed despite, treatment with rituximab (MabThera) or a ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment for ... Read more